Journals / Retina-Vitreus / 2009 / Cilt: 17 - Sayı: 3

Assessment of neovascular armd activity with a new clinical activity scoring

Neovasküler senil maküla dejenerasyonunda lezyon aktivitesini değerlendirmede yeni bir klinik aktivite skorlaması

Pages
159–164
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It also has the potential to decrease the number of unnecessary treatments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:With the emergence of anti-VEGF treatment for neovascular age-related macular degeneration (AMD) lesions, it is becoming more and more important to assess the activity of the lesion to decide on additional treatments.
📊
Key Findings & Data:This is because of both economical problems related to high cost of the treatment as well as injection and drug related complication risks.
💡
Conclusion & Impact:It also has the potential to decrease the number of unnecessary treatments.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Maküler dejenerasyon · Vitreus içi enjeksiyon · Macular Degeneration

Abstract

With the emergence of anti-VEGF treatment for neovascular age-related macular degeneration (AMD) lesions, it is becoming more and more important to assess the activity of the lesion to decide on additional treatments. This is because of both economical problems related to high cost of the treatment as well as injection and drug related complication risks. Nobody is sure about when to stop treatment and when to treat. There are no clear criteria to define an active lesion and to define the response of the lesion to the treatment. Here, an activity scoring system (ASS) which can easily be applied to all of the CNV lesions is suggested to define the lesions by quantifying the activity to determine the need for treatment. This ASS uses, presence of subretinal or intraretinal fluid in Optical Coherence Thomography (OCT), haemorrhage associated with the lesion, Florescein Angiography (FA) staining pattern, change in size of the lesion and changes in objective (measured) visual acuity and subjective vision (what the patient feels). Implementing an activity scoring system can assist in standardizing the assessments of activity of neovascular AMD lesions and assess the treatment effects. It also has the potential to decrease the number of unnecessary treatments.

Özet

Neovasküler senil maküla dejenerasyonu (SMD) tedavisi son yıllarda anti-VEGF ilaçlar ile farklı bir boyut kazanmış ve artık tedavi hedefi sadece görme kaybını önlemek değil, görmede artış sağlamak haline gelmiştir. Bu ilaçların yüksek maliyeti ve tekrarlayan intravitreal enjeksiyon gerektirmelerine bağlı muhtemel komplikasyonlar nedeniyle tedavi sayısını minimumda tutmak önemlidir. Aktif olduğu düşünülen lezyon tedavi edilmelidir. Fakat hangi lezyon aktiftir konusu her zaman net değildir ve değerlendiren kişiye bağlı olarak farklı kararla alınmaktadır. Burada lezyon aktivitesini ve tedaviye cevabı değerlendirmede Optical Coherence Thomography (OCT), lezyonla birlikte olan kanama, Florescein Angiography (FA) boyanma paterni, lezyon alanı, görmede objektif ve subjektif değişimlerin skorlanması ile elde edilen bir aktivite skorlaması sunularak bu konudaki belirsizliklerin giderilmesi amaçlanmıştır. Böylece gereksiz tedavilerden kaçınılması ve değerlendirmede bir standardizasyon sağlanması mümkün olabilecektir

🔖

Cite This Article

ÖZDEK, Ş. (2009). Assessment of neovascular armd activity with a new clinical activity scoring. Retina-Vitreus, Cilt: 17 - Sayı: 3, 159–164. https://ajindex.com/articles/305148

References (10)

  1. Schmidt-Erfurth UM, Richard G, Augustin A, et al.: European Society for Retina Specialists’ Guidelines Committee (EURETINA). Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486-494
  2. Huang D, Lin CP, Schuman JS, et al.: Optical coherence tomography. Science. 1991;22;254 3. van Velthoven ME, de Smet MD, Schlingemann RO, et al.: Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT. Graefes Arch Clin Exp Ophthalmol. 2006;244:1119-1123
  3. Salinas-Alamán A., García-Layana A., Maldonado MJ. et al.: Using optical coherence tomography to monitor photodynamic therapy in age related macular degeneration. Am J Ophthalmol. 2005;140:23-28
  4. Cohen SY, Korobelnik JF, Tadayoni R, et al.: Monitoring anti-VEGF drugs for treatment of exudative AMD. J Fr Ophtalmol. 2007;30:330-334
  5. Krebs I, Ansari-Shahrezaei S, Goll A, et al.: Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol. 2008;246:811-815
  6. Eter N, Spaide RF.: Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina. 2005;25:691-696
  7. Unver YB, Yavuz GA, Bekiroğlu N, et al.: Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. Eye. 2009;23:453-460
  8. Rosenfeld PJ, Rich RM, Lalwani GA.: Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006;19:361-372 10. Ozdek S, Hondur A, Gurelik G, et al.: Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol. 2005;26:127-133
  9. Ozdek S, Bozan E, Gurelik G, et al.: Transpupillary thermotherapy for the treatment of choroidal neovascularization secondary to angioid streaks. Can J Ophthalmol. 2007;42:95-100
  10. Brown DM, Regillo CD.: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144:627-637.